IFNAR1 and colorectal carcinoma: On the contrary, the notion that a minority of IFNα-treated animals develop small intrahepatic lesions that display similar proliferation, neoangiogenic and immunologic markers than untreated lesions highlights the possibility that CRC tumors, once established as macroscopic metastases, may become refractory and resistant to IFNα therapy by downregulating Ifnar1 (Boukhaled et al., 2021; Katlinski et al., 2017).